<DOC>
	<DOC>NCT01307033</DOC>
	<brief_summary>This study is being conducted to evaluate the safety of MK-0954A (L100/H12.5 mg) in essential hypertension participants who are uncontrolled with MK-954H (L50/H12.5 mg).</brief_summary>
	<brief_title>A Long-term Study of the Safety of MK-0954A in Patients With Essential Hypertension (MK-0954A-351)</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Hydrochlorothiazide</mesh_term>
	<mesh_term>Losartan</mesh_term>
	<criteria>Inclusion criteria: Participant has a diagnosis of essential hypertension. Participant is being treated with a single, or dual combination treatment for hypertension and will be able to discontinue the prior antihypertensive medication. Participant has a mean trough SiDBP of &gt;=90mmHg and &lt; 110mmHg. Participant has a mean trough SiSBP of &gt;=140mmHg and &lt; 200mmHg. Participant has no clinically significant abnormality at screening visit. Exclusion criteria: Participant is currently taking &gt; 2 antihypertensive medications. Participant has a history of significant multiple and/or severe allergies to ingredients of Nulotan or Preminent and thiazide drug or related drug (i.e., sulfonamidecontaining "chlortalidone" medicines). Participant is, at the time of signing informed consent, a user of recreational or illicit drugs or has had a recent history within the last year of drug or alcohol abuse or dependence. Participant is pregnant or breastfeeding, or expecting to conceive or the pregnancy test is positive at screening visit. Participant is currently participating or has participated in a study with an investigational compound or device within 30 days of signing informed consent.</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>Essential hypertension</keyword>
	<keyword>Uncontrolled hypertension</keyword>
	<keyword>Antihypertensive agents</keyword>
	<keyword>Blood pressure</keyword>
</DOC>